Compounds > sc-46275
Page last updated: 2024-12-10

sc-46275

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5311427
CHEMBL ID49922
MeSH IDM0195537

Synonyms (25)

Synonym
137255-19-7
fz6t2mqr9r ,
unii-fz6t2mqr9r
methyl 7-(2beta-(6-(1-cyclo-pentyl-yl)-4r-hydroxy-4-methyl-1e,5e-hexadienyl)-3alpha-hydroxy-5-oxo-1r,1alpha-cyclopentyl)-4z-heptenoate
4-heptenoic acid, 7-(2-(6-(1-cyclopenten-1-yl)-4-hydroxy-4-methyl-1,5-hexadienyl)-3-hydroxy-5-oxocyclopentyl)-, methyl ester, (1r-(1alpha(z),2beta(1e,4r*,5e),3alpha))-
sc46275
sc-46275 ,
CHEMBL49922
methyl (z)-7-[(1r,2r,3r)-2-[(1e,4r,5e)-6-(cyclopenten-1-yl)-4-hydroxy-4-methylhexa-1,5-dienyl]-3-hydroxy-5-oxocyclopentyl]hept-4-enoate
gtpl3331
methyl (4z)-7-[(1r,2r,3r)-2-[(1e,4r,5e)-6-(cyclopent-1-en-1-yl)-4-hydroxy-4-methylhexa-1,5-dien-1-yl]-3-hydroxy-5-oxocyclopentyl]hept-4-enoate
remiprostol, (1r,2r,3r,4'r)-
4-heptenoic acid, 7-(2-(6-(1-cyclopenten-1-yl)-4-hydroxy-4-methyl-1,5-hexadienyl)-3-hydroxy-5-oxocyclopentyl)-, methyl ester, (1r-(1.alpha.(z),2.beta.(1e,4r*,5e),3.alpha.))-
4-heptenoic acid, 7-((1r,2r,3r)-2-((1e,4r,5e)-6-(1-cyclopenten-1-yl)-4-hydroxy-4-methyl-1,5-hexadien-1-yl)-3-hydroxy-5-oxocyclopentyl)-, methyl ester, (4z)-
sc 46275
4-heptenoic acid, 7-(2-(6-(1-cyclopenten-1-yl)-4-hydroxy-4-methyl-1,5-hexadienyl)-3-hydroxy-5-oxocyclopentyl)-, methyl ester, (1.alpha.(z),2.beta.(1e,4r*,5e),3.alpha.)-(+/-)-
4-heptenoic acid, 7-((1r,2r,3r)-2-((1e,4r,5e)-6-(1-cyclopenten-1-yl)-4-hydroxy-4-methyl-1,5-hexadien-1-yl)-3-hydroxy-5-oxocyclopentyl)-, methyl ester, (4z)-rel-
unii-nyg10z50bh
nyg10z50bh ,
remiprostol, (1s,2s,3s,4's)-(+/-)-
110902-56-2
4-heptenoic acid, 7-(2-(6-(1-cyclopenten-1-yl)-4-hydroxy-4-methyl-1,5-hexadienyl)-3-hydroxy-5-oxocyclopentyl)-, methyl ester, (1alpha(z),2beta(1e,4r*,5e),3alpha)-(+/-)-
remiprostol, (1r,2r,3r,4'r)-(+/-)-
Q27088746
AKOS040753962

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" bioavailability in unoperated fasted dogs."( SC-46275: a potent, long-acting gastric antisecretory prostaglandin with low oral bioavailability in the dog.
Bauer, RF; Burton, EG; Casler, JJ; Collins, PW; Gaginella, TS; Gasiecki, AF; Jones, PH; Perkins, WE; Tsai, BS, 1991)		1.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID59834Gastric antisecretory activity in food stimulated pavlov dogs by intrapouch administration1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of acyclic omega chain conjugated diene analogues of enisoprost.
AID229654Selectivity ratio was evaluated by the quotient of diarrheal ED50 value divided by antisecretory ED50 x 10 E-31992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of acyclic omega chain conjugated diene analogues of enisoprost.
AID177069Compound was evaluated for diarrheagenic side effects in adult male rats by intragastric administration1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of acyclic omega chain conjugated diene analogues of enisoprost.
AID60034Tested for gastric antisecretory activity in dogs by intrapouch administration1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Chemistry and structure-activity relationships of C-17 unsaturated 18-cycloalkyl and cycloalkenyl analogues of enisoprost. Identification of a promising new antiulcer prostaglandin.
AID176830Tested for diarrheal side effects in rats by intragastric administration1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Chemistry and structure-activity relationships of C-17 unsaturated 18-cycloalkyl and cycloalkenyl analogues of enisoprost. Identification of a promising new antiulcer prostaglandin.
AID1346396Rat EP3 receptor (Prostanoid receptors)2006Prostaglandins, leukotrienes, and essential fatty acids, Jun, Volume: 74, Issue:6
Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (66.67)18.2507
2000's3 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.95 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nifedipine
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.		2.0310C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
phenylephrine
Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.		2.0310phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
tenidap
tenidap: structure given in first source; RN refers to (Z)-isomer		2.9110
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		4.0250prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
alprostadil
[no description available]		4.370prostaglandins Eanticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent
misoprostol
Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.. misoprostol : A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.		8.5930
17-phenyltrinorprostaglandin e2
17-phenyltrinorprostaglandin E2: an EP1 receptor agonist. 17-phenyl-18,19,20-trinor-prostaglandin E2 : A prostanoid that is 18,19,20-trinor-prostaglandin E2 in which one of the terminal methyl hydrogens has been replaced by a phenyl group.		210alicyclic ketone;
beta-hydroxy ketone;
hydroxy monocarboxylic acid;
olefinic compound;
oxo monocarboxylic acid;
prostanoid;
secondary alcohol		human metabolite;
prostaglandin receptor agonist
ah 23848
AH 23848: thromboxane antagonist. AH23848 : A racemate comprising equimolar amounts of (1R,2R,5S)- and (1S,2S,5R)-enantiomers of (4Z)-7-{5-[([1,1'-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl}hept-4-enoic acid. The hemicalcium salt is a potent, specific thromboxane receptor-blocking drug that is orally active and has a long duration of action.. (1R,2R,5S)-AH23848 : A (4Z)-7-{5-[([1,1'-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl}hept-4-enoic acid in which the stereocentres at positions 1, 2 and 5 have R-, R- and S-configuration respectively.		210(4Z)-7-{5-[([1,1'-biphenyl]-4-yl)methoxy]-2-(morpholin-4-yl)-3-oxocyclopentyl}hept-4-enoic acid
cicaprost
cicaprost: RN given refers to (3aS-(2E,3aalpha,4alpha(3R*,4R*),5beta,6aalpha))-isomer		210monoterpenoid
fluprostenol
fluprostenol: synthetic prostaglandin F 2 alpha analog used as an abortifacient; RN given refers to ((1alpha(Z),2beta(1E,3R*),3alpha,5alpha)-(+-))-isomer. fluprostenol : An organofluorine compound that is racemic prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of its isopropyl ester prodrug, travoprost, are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. The isopropyl ester group of travoprost is hydrolysed to the biologically active free acid by esterases in the cornea.		2.0310(trifluoromethyl)benzenes;
hydroxy monocarboxylic acid;
prostaglandins Falpha		abortifacient;
antiglaucoma drug;
antihypertensive agent;
female contraceptive drug;
prostaglandin receptor agonist
enisoprost
[no description available]		2.6730
taprostene
[no description available]		210benzoic acids
sulprostone
sulprostone: structure		2.6930prostanoid
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid: A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)		2.0310
17,20-dimethylisocarbacyclin
17,20-dimethylisocarbacyclin: improves hypothermic preservation of rat liver		210
butaprost
butaprost: highly selective prostaglandin receptor agonist; structure given in first source		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Diarrhea
An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.		02.3820
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0310
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9810